Ustekinumab-auub - Biologic Drug Details

Summary for ustekinumab-auub

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	2
Suppliers: see list	1

Pharmacology for ustekinumab-auub

Mechanism of Action	Interleukin-12 Antagonists Interleukin-23 Antagonists
Established Pharmacologic Class	Interleukin-12 Antagonist Interleukin-23 Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ustekinumab-auub Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ustekinumab-auub Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ustekinumab-auub Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Ustekinumab-auub

Last updated: February 20, 2026

What is Ustekinumab-auub?

Ustekinumab-auub is a biosimilar of the biologic drug ustekinumab, marketed as Stelara by Janssen. It is designed to treat autoimmune conditions such as psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. It received regulatory approval in the United States and Europe in 2023 for specific indications, with commercialization expected to follow swiftly.

Market Landscape

Original Biologic: Ustekinumab (Stelara)

• Market Size (2022): Approximately $6.4 billion globally.
• Indications: Psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis.
• Sales Trends: Steady growth at around 10% CAGR over the past five years.
• Patent Expiry: Ustekinumab’s primary patents expire from 2026 to 2028, opening potential for biosimilar entry.

Biosimilar Manufacturer: Ustekinumab-auub

• Approval Date: U.S. FDA approved in March 2023; EMA approved in April 2023.
• Market Entry: Expected commercial launch in late 2023 to early 2024.
• Pricing Strategy: Approximately 15-20% below the reference product, aligned with biosimilar pricing standards.

Competitors

• Other biosimilars targeting ustekinumab, such as those from Sandoz and Biocon, are in late-stage development.
• Existing biologic competitors include adalimumab (Humira), infliximab (Remicade), holding significant market share, though ustekinumab maintains a niche due to unique efficacy profile.

Market Dynamics

Price Competition and Market Share

• Biosimilars typically capture 25-35% of the biologic’s market within two years of entry.
• Initial market penetration for ustekinumab-auub projected at 10-15% in the first year, rising as physicians adopt biosimilars for cost savings.
• Price reductions driven by biosimilar entry contribute to overall market contraction of original biologics.

Reimbursement and Regulatory Environment

• Coverage policies favor biosimilars for cost reductions.
• CMS and other insurers have policies incentivizing biosimilar use, influencing prescribing behaviors.

Adoption Drivers and Barriers

• Drivers: Lower prices, equal efficacy, increased access.
• Barriers: Physician preference for original biologic, patient perceptions, supply chain integration.

Financial Trajectory

Year	Estimated Sales (USD billion)	Market Share	Comments
2023	$0.2 billion	2-4%	Launch year, limited supply, cautious adoption
2024	$0.4 billion	10-15%	Increased physician familiarity, early uptake
2025	$0.8 billion	20-25%	Broadened access, formulary inclusion
2026+	$1.2+ billion	30%+	Stabilized market share, competition intensifies

Revenue Assumptions

• Biosimilar pricing at 15-20% discount.
• Conversion rates to biosimilar therapy increase as trust builds.
• Market penetration accelerates with educational outreach and formulary win.

Cost Structure

• Development costs recouped prior to approval.
• Manufacturing costs lower than originator due to streamlined processes.
• Marketing expenses focused on prescriber education and payer engagement.

Risks and Opportunities

• Regulatory Delays: Any delays in approval or market access could push the trajectory back.
• Manufacturing Challenges: Quality issues could impact supply and reputation.
• Market Competition: Arrival of multiple biosimilars could pressure prices and margins.
• Reimbursement Policies: Changes could either facilitate or hinder biosimilar uptake.

Key Takeaways

• Ustekinumab-auub is entering an established yet evolving market with significant upside potential.
• The biosimilar is positioned for rapid adoption, especially if it delivers cost savings and comparable efficacy.
• Market share growth depends on competitive dynamics, payer policies, and physician acceptance.
• Financial projections indicate moderate early revenue growth accelerating in subsequent years.

FAQs

1. When is ustekinumab-auub expected to reach peak sales?
Peak sales are expected around 2028, with anticipated revenues exceeding $2 billion globally, contingent on market competition and adoption rates.

2. How does biosimilar pricing compare to the originator?
Biosimilars typically price 15-20% below the original biologic, driving cost savings for healthcare systems.

3. What are the primary barriers to biosimilar adoption?
Physician familiarity with the original biologic, patient perceptions, and formulary restrictions impede immediate uptake.

4. How might patent litigation impact market entry and sales?
Potential patent disputes could delay market entry. Successful litigation or patent expiry would enable more biosimilars and increased competition.

5. What strategic actions should biosimilar developers prioritize?
Focus on securing formulary inclusion, educating physicians, ensuring supply chain robustness, and differentiating through cost savings.

---

References

1. Market Research Future. (2022). Global Ustekinumab Market Analysis.
2. IQVIA. (2022). Top-selling biologics and biosimilars report.
3. U.S. Food and Drug Administration. (2023). Ustekinumab-biologic Biosimilar Approval Announcement.
4. European Medicines Agency. (2023). Biosimilar Ustekinumab Data.
5. Evaluate Pharma. (2022). Biosimilars Market Outlook.